Clinical Trial Update: Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This is a Phase II trial update of Cabazitaxel-XRP6258 in advanced non-small cell lung cancer (Stage IV/metastatic). Results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cabazitaxel-XRP6258 (cabazitaxel)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Non-small Cell Lung Cancer (NSCLC), Stage IV NSCLC | Phase 2 | Status: COMPLETED | Results posted: 2017-05-24